Krystal Biotech (KRYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovitz from Citi maintained a Hold rating on the stock and has a $155.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Yigal Nochomovitz has given his Hold rating due to a combination of factors influencing Krystal Biotech’s current market position. The recent financial results have indicated a slowdown in the growth dynamics of Vyjuvek in the US, prompting a downward revision of its peak sales estimates both domestically and globally. This adjustment reflects a more moderated outlook as the transition of patients to maintenance therapy takes longer than initially expected.
Despite the stock’s recent pullback, Nochomovitz maintains a neutral stance, noting that the current valuation does not fully account for the potential of Krystal’s pipeline. The possibility of stronger-than-anticipated performance in European markets, particularly Germany, could lead to an upward revision of forecasts. However, until further de-risking occurs, a conservative approach is warranted, with a cautious probability of success assigned to the company’s pipeline projects.